News

Cathy Tie slips on a white lab coat bearing her name and the logo of her startup: Origin Genomics. "Welcome!" she says as she leads an NPR reporter, photographer and videographer on an exclusive tour of Origin's labs located...

This is the 17th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. The series is organized by Osagie K. Obasogie in...

THE INSTAGRAM POST, precision-guided by sex and age, had zeroed in on its target. Yuchen Tu is a conser­vatory-trained viola...

This is the 16th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring...

purple cancer cells
By Michael Le Page, New Scientist | 12.11.2022

A teenager with aggressive leukaemia now has no detectable cancer cells after becoming the first person to receive a treatment...

crispr
By Fyodor Urnov, The New York Times | 12.09.2022

The parents of a 2-year-old girl write that their daughter “could die within the next year” because a genetic mutation...

He Jiankui at his panel in 2018
By Peter McKnight, Vancouver Sun | 12.08.2022

When a scientist announces the opening of a new laboratory, it doesn’t ordinarily make news around the world. But Chinese...

state capitol building
By Nick Reynolds, Newsweek | 12.07.2022

A West Virginia lawmaker is proposing legislation to stop drug offenders from having children in an effort to reduce the...

police in riot gear
By Niha Masih, The Washington Post | 12.07.2022

San Francisco’s Board of Supervisors voted Tuesday to bar police from using robots to kill, in a striking reversal that...

a dna double helix
By Anna Clark, Adriana Gallardo, Jenny Deam and Mariam Elba, ProPublica | 12.06.2022

Amanda wanted to warn someone. In June 2021, her daughter — the one she and her husband had tried for...

neuron
By Gina Kolata, The New York Times | 12.05.2022

In a bold attempt to stop the progress of some cases of Alzheimer’s disease, a group of researchers is trying...

FDA logo
By Nick Paul Taylor, Fierce Biotech | 12.05.2022

The FDA has set out its reasons for putting Verve Therapeutics’ high cholesterol gene editing therapy on hold. Officials want...